---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-139366"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:22:01.434501+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete

## Summary
- Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.
- Cash and equivalents $48.7M as of March 31, 2024, down from $57.4M at Dec 31, 2023.
- Phase 3 Orbit study (setrusumab) fully enrolled (158 patients); Cosmic enrolled 69 patients.
- Alvelestat SGRQ validation completed; Phase 3 protocol to be submitted to FDA in H1 2024.
- Cash guidance unchanged: funds operations into 2026; no alvelestat partnership upfront included.

## SEC filing metadata
- accession: 0001193125-24-139366
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/0001193125-24-139366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524139366/d787110d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-139366
- JSON: https://secwatch.observer/filing/0001193125-24-139366.json
- Plain text: https://secwatch.observer/filing/0001193125-24-139366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.